Quick Answer
Chemomab Therapeutics Ltd. reported Stockholders Equity of $12.33 million for the year ending 2025.
- Chemomab Therapeutics Ltd. showed a decrease of -8.9% in Stockholders Equity from 2024 to 2025.
- This data is from Chemomab Therapeutics Ltd.'s annual report (Form 10-K), filed with the SEC on March 23, 2026.
- XBRL data for this metric is available from 2017 to 2025 (9 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $31.34 million | Q2 2019: $27.25 million | Q3 2019: $20.40 million | Q1 2020: $10.72 million | Q2 2020: $12.80 million | Q3 2020: $12.16 million | Q1 2021: $55.16 million | Q2 2021: $68.04 million | Q3 2021: $65.51 million | Q1 2022: $57.24 million | Q2 2022: $51.84 million | Q3 2022: $44.62 million | Q1 2023: $27.95 million.
- Over the full 9 years of available data (2017 to 2025), Chemomab Therapeutics Ltd.'s Stockholders Equity has grown by 2,125.3%.
- Historical annual values: Fiscal year 2025: $12.33 million | Fiscal year 2024: $13.54 million | Fiscal year 2023: $17.00 million | Fiscal year 2022: $36.22 million | Fiscal year 2021: $61.47 million | Fiscal year 2020: $10.80 million | Fiscal year 2019: $12.37 million | Fiscal year 2018: $9.81 million | Fiscal year 2017: -$609.0 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: